Author:
Takahashi Naoto,Miura Ikuo,Kobayashi Yoshimi,Kume Masaaki,Yoshioka Tomoko,Otane Wataru,Ohtsubo Kaori,Takahashi Kaoru,Kitabayashi Atsushi,Kawabata Yoshinari,Hirokawa Makoto,Nishijima Hirokazu,Ichinohasama Ryo,DeCoteau John,Miura Akira B.,Sawada Ken-ichi
Publisher
Springer Science and Business Media LLC
Reference31 articles.
1. O'Brien SG, Guilhot F, Larson RA, et al, for the IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004.
2. Kantarjian H, Sawyer C, Hochhaus A, et al, for the International STI571 CML Study Group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652.
3. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003;102:276-283.
4. Hansen JA, Gooley TA, Martin PJ, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med. 1998;338:962-968.
5. Gratwohl A, Hermans J, Goldmon JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation: Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 1998;352:1087-1092.
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献